

Executive Commentary

Executive Commentary

Introduction

For the first time since 1992, the number of U.S. TB cases reported to the National Tuberculosis (TB) Surveillance System (NTSS) increased over the previous year. In 2015, the 50 United States and the District of Columbia reported 9,557 TB cases to CDC, representing a 1.6% increase from 2014 (Table 1). Twenty-seven states and the District of Columbia reported increased case counts from 2014 (Table 30), and four states (California, Texas, New York, and Florida) accounted for 50.6% of the national case total (Table 31). Despite this slight increase in case count, the TB incidence rate per 100,000 persons has remained relatively stable at approximately 3.0 since 2013 (Table 1). Seven states and the District of Columbia reported incidence rates above the national average (Table 30). The National Center for Health Statistics reported 493 deaths in 2014 (the most recent year for which mortality data are available) that were attributable to TB, an 11.2% decrease from 2013 (Table 1).

NTSS Description

Since 1953, in cooperation with state and local health departments, the United States national tuberculosis program has collected information on each newly reported case of tuberculosis (TB) disease in the United States. In 1985, CDC began collecting individual TB case reports using the Report of Verified Case of Tuberculosis (RVCT). The RVCT was expanded in 1993 in response to the TB epidemic of the late 1980s and early 1990s, and reporting areas began submitting the RVCT electronically via the TB Information Management System (TIMS). CDC has maintained a dynamic TB surveillance case registry since 1993. In 2009, CDC expanded the RVCT again and reporting areas transitioned from TIMS to data collection via the Public Health Information Network/National Electronic Disease Surveillance System.

In addition to the 50 United States and the District of Columbia, CDC accepts TB case reports from four U.S. insular areas (American Samoa,

Guam, Puerto Rico, and the U.S. Virgin Islands) and four sovereign nations that have signed compacts of free association with the United States (Commonwealth of the Northern Mariana Islands, Federated States of Micronesia, Republic of the Marshall Islands, and Republic of Palau). In this report, these sovereign nations are referred to as “freely associated states.”

Each annual TB surveillance report includes updated case counts for each year in the dynamic surveillance database, starting in 1993 through the newly available data. Reporting areas update past years’ data as needed and accordingly data for past years might not match data published in previous annual reports. This annual summary contains information through 2015.

Demographics

Overall since 1993, TB incidence rates have declined in almost all racial and ethnic groups: among American Indian/Alaska Natives, from 14.4 to 6.1 cases/100,000 persons (–57.6%); among Asians, from 42.2 to 18.2 cases/100,000 (–56.9%); among non-Hispanic blacks/African Americans, from 29.1 to 5.0 cases/100,000 (–82.8%); among non-Hispanic whites, from 3.6 to 0.6 cases/100,000 (–83.3%); and among Hispanics/Latinos, the decline has been from 20.4 to 4.8 cases/100,000 (–76.5%). However, since 2013, TB incidence rates have increased among American Indian/Alaska Natives (+12.3%), Native Hawaiian/Other Pacific Islanders (+59.7%), and persons reporting multiple races (+4.8%), although these increases should be interpreted with caution because of the small sizes of the underlying populations. Since 2013, TB incidence rates have continued to gradually decline among non-Hispanic blacks/African Americans (–6.4%), non-Hispanic whites (–12.1%), and Hispanics/Latinos (–4.0%). While the TB incidence rate for Asians also declined from 2013 to 2015 (–1.0%), in 2015 the overall TB incidence rate for Asians remained over three times higher than that for Hispanics/Latinos or blacks/African Americans (Table 2).

Although the incidence rates for both the foreign-born and the U.S.-born populations have declined substantially since 1993, the decline has been less among the foreign-born (–55.6%) than among the U.S.-born (–83.8%) (Table 5). Foreign-born persons are defined as anyone born outside of the United States or U.S. insular areas and freely associated states (with the exception of those born abroad to U.S. parents). This includes naturalized U.S. citizens, permanent residents, visitors, persons with student or work visas, refugees, and persons with undocumented or unknown immigration status. The burden of TB was markedly different between foreign-born and U.S.-born populations at 15.1 and 1.2 cases/100,000 persons, respectively, which is roughly a 13-fold difference (Table 5). The majority of these cases progressed from latent TB infection acquired years in the past.

Foreign-born persons continued to represent the majority of U.S. TB cases (66.4%), roughly the same proportion as in 2014 (Table 5), and in 36 states and the District of Columbia, $\geq 50\%$ of TB cases occurred among foreign-born persons (Table 34). Asians represented nearly half (47.8%) of the reported foreign-born TB cases in 2015 (Table 19). Hispanics comprised the second largest group of foreign-born TB cases (32.0%, Table 19). In comparison, among U.S.-born persons, blacks/African Americans represented the largest percentage (35.9%) of TB cases, followed by whites at 31.1% (Table 18).

Collecting information on country of birth can help direct TB prevention efforts, both primary prevention efforts around the world, as well as secondary prevention efforts in the United States to screen and treat individuals for latent TB infection. From 2011 through 2015, the top five countries of origin of foreign-born persons with TB were Mexico, the Philippines, India, Vietnam, and China (Table 6). The distribution of TB cases among foreign-born persons by world region of origin is influenced by the size of the total population from those regions living in the

United States, as well as the prevalence of TB in those regions.

Of the 6,350 TB cases reported among foreign-born persons in 2015, the majority of cases occurred among persons born in the Americas region (35.7%), and those born in the Western Pacific region (32.6%), which is similar to the distribution of cases by world region of origin in 2014 (Table 20). From 1993 through 2015, the percentage of cases increased among persons born in the Eastern Mediterranean region (2.8% in 1993 to 4.6% in 2015), the Southeast Asia region (5.6% in 1993 to 15.7% in 2015), and the Africa region (2.4% in 1993 to 8.7% in 2015) (Table 20).

In 2015, TB incidence rates continued to decline for persons < 5 years old and 15–24 years old; however the incidence rate for persons 45–64 years old increased slightly from 3.5 to 3.6 cases/100,000 persons. Incidence rates for all other age groups remained similar to 2014. The highest burden of disease continues to be among older adults. In 2015, adults ≥ 65 years old had an incidence rate of 4.8 cases/100,000, while children 5–14 years old had the lowest rate at 0.5 cases/100,000 (Table 4).

HIV Coinfection

The proportion of TB cases with a reported HIV test result who were coinfecting with HIV has decreased from 48.2% in 1993 to 5.5% in 2015. In the past 3 years, this proportion has declined from 6.4% in 2013 to 5.5% in 2015 (Table 11).

TB Treatment Regimens and Drug Resistance

The proportion of TB patients prescribed the recommended initial treatment regimen including isoniazid, rifampin, pyrazinamide, and ethambutol increased from 40.3% in 1993 to 84.7% in 2015. The proportion of patients who completed therapy within 1 year increased from 63.4% in 1993 to 89.6% in 2013 (the latest year for which complete outcome data are available). The proportion of persons receiving directly observed therapy for at least a portion of the treatment

duration also increased from 36.1% in 1993 to 92.1% in 2013 (Table 10).

In 2015, 1.1% of reported TB cases had primary multidrug resistance (MDR), defined as no previous history of TB disease and resistance to at least isoniazid and rifampin (Table 9). This percentage has remained stable, fluctuating between 0.9% and 1.3% since 1996. The proportion of primary MDR TB occurring in foreign-born persons has increased from 25.3% (103 of 407) in 1993 to 86.3% (63 of 73) in 2015, which is similar to the proportion in 2014 (Table 9). In 2015, there was one case reported of extensively drug-resistant (XDR) TB, defined as resistance to isoniazid and rifampin, plus resistance to any fluoroquinolone and at least one of three injectable second-line anti-TB drugs (i.e., amikacin, kanamycin, or capreomycin).

Genotyping

TB genotyping is a laboratory-based analysis of the genetic material of the bacteria that cause TB disease. TB genotype clusters are defined as two or more cases with matching genotypes in the same county during a 3-year time period. Cases that are clustered may be the consequence of recent transmission, while unique cases are more likely attributable to reactivation of infection that was acquired in the past. Among genotyped cases during 2013–2015, 21.5% were clustered (Table 23). During this period, the percentage of clustered cases among U.S.-born persons with TB was 36.0%, compared to 14.4% among foreign-born persons diagnosed with TB in the United States (Table 22). However, not all clustered cases result from recent transmission.

In 2015, CDC scientists developed and published a new genotype-based method to estimate the proportions of cases attributable to recent transmission in defined populations (e.g., geographic areas).¹ The method, which was validated using epidemiologic data, attempts to identify a “plausible-source case” for each genotyped TB case using a combination of genotyping and spatial, temporal, clinical, and demographic criteria. In

2016, an estimate was published that approximately 14% of genotyped cases during 2011–2014 were attributed to recent transmission.³ The method also was refined by distinguishing limited versus extensive recent transmission based on the size of plausible transmission clusters. State-level estimates were published.³

Conclusions

The overall number of TB cases in the United States increased in 2015 compared with the previous year, after having declined yearly during 1993–2014. The increase in the overall case count in 2015 and leveling of the U.S. incidence rate since 2013 raise concern that current TB control practices might no longer be sufficient to sustain the previously observed rate of decrease in U.S. TB incidence. Statistical modeling has shown that decreasing the prevalence of latent TB infection will also be key to eliminating TB in the United States.² Resuming and accelerating progress toward TB elimination will require an intensified, dual approach that includes strengthening existing systems to prevent transmission of infectious TB disease and increasing efforts to detect and treat latent TB infection.

CDC continues to work with its partners to achieve the goal of TB elimination in the United States. Current TB control strategies prioritize the early diagnosis, isolation, and treatment of people with infectious TB disease. This approach protects patients’ health, prevents transmission to others, and allows for timely contact investigations to detect and prevent additional cases. These TB control efforts are essential, but by themselves cannot eliminate the disease from the United States. More than 85% of U.S. TB cases are associated with longstanding, untreated latent TB infections, and public sector efforts alone will be insufficient to reach all of those who need to be tested and treated for latent TB.² These efforts must also include public health systems and private providers, who are often on the front lines of health care in the communities most affected by TB.

Global TB disease burden and the incidence in the United States are closely related, emphasizing the continued need to strengthen existing support for TB control efforts abroad. This is particularly true as relates to the countries of persons who have lived in countries where TB disease is more common. Foreign-born persons continue to be disproportionately affected by TB; now accounting for 66.4% of total cases. To achieve TB elimination, intensified efforts continue to be needed to address the persistent disparities that exist between U.S.-born and foreign-born persons, as well as among U.S.-born racial and ethnic minorities.

Ongoing surveillance and improved TB control and prevention activities will be essential in light of the increase in TB case count in 2015 and the leveling of U.S. TB incidence rates in recent years. CDC also continues to study available data on TB and latent TB infection trends in the United States to better inform TB prevention and control efforts. Ultimately TB elimination will require a sustained focus on domestic TB control, a strengthened effort to diagnose and treat latent TB infection, and continued support of global TB control initiatives.

References

1. France AM, Grant J, Kammerer JS, Navin TR. A field-validated approach using surveillance and genotyping data to estimate tuberculosis attributable to recent transmission in the United States. Am J Epidemiol 2015; 182: 799-807.
2. Hill AN, Becerra J, Castro KG. Modeling tuberculosis trends in the USA. Epidemiol Infect 2012; 140: 1862-1872.
3. Yuen CM, Kammerer JS, Marks K, Navin TR, France AM. Recent Transmission of Tuberculosis - United States, 2011-2014. PLoS One 2016; 11: e0153728.